Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.73
+0.2%
$2.69
$1.83
$7.48
$2.41B0.087.65 million shs715,171 shs
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
$15.96
-2.8%
$18.84
$0.89
$27.95
$682.51M2.18386,531 shs165,746 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$36.08
+1.4%
$33.40
$27.12
$60.90
$2.19B2.41963,694 shs29,460 shs
Vericel Corporation stock logo
VCEL
Vericel
$40.22
+2.0%
$41.70
$37.39
$63.00
$2.03B1.32416,322 shs4,841 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+0.74%+3.03%-13.65%+12.40%-57.23%
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
0.00%-0.73%-14.79%+30.11%+31.05%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.61%-3.26%+12.73%+1.17%-26.57%
Vericel Corporation stock logo
VCEL
Vericel
-5.68%-7.38%-8.98%+2.10%-15.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.2713 of 5 stars
3.61.00.00.02.41.70.6
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.5231 of 5 stars
4.42.00.04.43.40.80.6
Vericel Corporation stock logo
VCEL
Vericel
2.9583 of 5 stars
3.51.00.00.03.30.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$12.25349.54% Upside
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
0.00
N/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4039.70% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1452.04% Upside

Current Analyst Ratings Breakdown

Latest TALS, TWST, IBRX, and VCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/4/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/3/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/28/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/20/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$4.25 ➝ $5.00
5/12/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/12/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M163.17N/AN/A($0.57) per share-4.78
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
N/AN/AN/AN/A$4.33 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.91N/AN/A$8.07 per share4.47
Vericel Corporation stock logo
VCEL
Vericel
$238.54M8.49$0.30 per share133.57$5.92 per share6.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
-$73.89M-$1.79N/AN/AN/A-39.93%-37.37%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,346.1291.40N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest TALS, TWST, IBRX, and VCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/12/2025Q1 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
2.22
2.05
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
N/A
15.41
15.41
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
67.61%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
16.50%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590882.62 million204.86 millionOptionable
Talaris Therapeutics, Inc. stock logo
TALS
Talaris Therapeutics
8442.76 million35.71 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million46.72 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.72 +0.01 (+0.18%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Talaris Therapeutics stock logo

Talaris Therapeutics NASDAQ:TALS

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$36.08 +0.49 (+1.37%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$40.22 +0.81 (+2.04%)
As of 09:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.